Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.70 |
| ▸ | NPC1 | O15118 | 4/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.70 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | AXL | P30530 | 1/20 | 0.61 |
| ▸ | GFER | P55789 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | SCN4A | P35499 | 3/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 2/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.51 |
| ▸ | PI4KA | P42356 | 2/20 | 0.51 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13780339 | 0.85 | RAB9A (0.81) | RAB9ANPC1SMN1; SMN2MAPTAXL | |
| SCHEMBL3113690 | 0.84 | RAB9A (0.72) | RAB9ANPC1SMN1; SMN2MAPTAXL | |
| SCHEMBL142514 | 0.82 | RAB9A (1.00) | RAB9ANPC1SMN1; SMN2MAPTAXL | |
| SCHEMBL31385162 | 0.82 | RAB9A (0.70) | RAB9ANPC1SMN1; SMN2MAPTAXL | |
| SCHEMBL27899294 | 0.82 | RAB9A (0.70) | RAB9ANPC1SMN1; SMN2MAPTAXL | |
| SCHEMBL785395 | 0.82 | RAB9A (0.70) | RAB9ANPC1SMN1; SMN2MAPTAXL | |
| SCHEMBL9475607 | 0.81 | RAB9A (0.64) | RAB9ANPC1SMN1; SMN2MAPTAXL | |
| SCHEMBL7130526 | 0.80 | RAB9A (0.73) | RAB9ANPC1SMN1; SMN2MAPTAXL | |
| SCHEMBL9722768 | 0.79 | RAB9A (0.66) | RAB9ANPC1SMN1; SMN2MAPTAXL | |
| SCHEMBL5164106 | 0.79 | RAB9A (0.66) | RAB9ANPC1SMN1; SMN2MAPTAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10208049-B2 | Compounds and methods of treating ocular disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180134714-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | CASE WESTERN RESERVE UNIVERSITY | 2018-05-17 | — | — | US | disclosed |
| US-20140357611-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR NIH | 2014-12-04 | — | — | US | disclosed |
| US-20140235604-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-08-21 | — | — | US | disclosed |
| US-8722669-B2 | Compounds and methods of treating ocular disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2014-05-13 | — | — | US | disclosed |
| US-20120295895-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-11-22 | — | — | US | disclosed |
| EP-2509596-A2 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | Case Western Reserve University (US) | 2012-10-17 | — | — | EP | disclosed |
| WO-2011071995-A2 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | CASE WESTERN RESERVE UNIVERSITY (US) | 2011-06-16 | — | — | WO | disclosed |
| EP-0282971-B1 | Substituted 2-aminobenzothiazoles and derivatives useful as cerebrovascular agents | WARNER LAMBERT CO (US) | 1994-12-28 | — | — | EP | disclosed |
| US-4971983-A | Use as anesthetics in surgery where a risk of cerebrovascular damage exists; e.g. riluzole | WARNER-LAMBERT COMPANY (US) | 1990-11-20 | — | — | US | disclosed |
| US-4918090-A | ADMINISTERING TO STROKE PATIENT | WARNER-LAMBERT COMPANY (US) | 1990-04-17 | — | — | US | disclosed |
| US-4826860-A | STROKES | WARNER-LAMBERT COMPANY (US) | 1989-05-02 | — | — | US | disclosed |
| EP-0282971-A2 | Substituted 2-aminobenzothiazoles and derivatives useful as cerebrovascular agents | WARNER-LAMBERT COMPANY (US) | 1988-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295895-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | ALDH1A2, NR2E3, LRAT | RAB9A 432/4885NPC1 29/4885SMN1; SMN2 489/4885 |
| US-20140357611-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | ALDH1A2, TYR, HRH2 | RAB9A 1363/4885NPC1 80/4885SMN1; SMN2 1417/4885 |
| US-20180134714-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | ALDH1A2, NR2E3, LRAT | RAB9A 432/4885NPC1 29/4885SMN1; SMN2 489/4885 |
| US-20140235604-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | ALDH1A2, NR2E3, LRAT | RAB9A 432/4885NPC1 29/4885SMN1; SMN2 489/4885 |
| US-10208049-B2 | Compounds and methods of treating ocular disorders | ALDH1A2, NR2E3, LRAT | RAB9A 432/4885NPC1 29/4885SMN1; SMN2 489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.